HLB BioStep Co

HLB BioStep Co Div.-Adj. PEG

The Dividend-Adjusted PEG Ratio of HLB BioStep Co (278650.KQ) as of Nov 2, 2026 is 0.11. In the previous year, Dividend-Adjusted PEG Ratio was 0.15 — a change of -24.74% (lower).

Div.-Adj. PEG

0.11

YoY

-24.74%

Last updated:

Dividend-Adjusted PEG Ratio of HLB BioStep Co is 2021 0.11 . Dividend-Adjusted PEG Ratio of HLB BioStep Co was 2020 0.15 . It decreases by -24.74% lower compared to the previous year.

The HLB BioStep Co Div.-Adj. PEG history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Div.-Adj. PEG
Date
Div.-Adj. PEG
Jan 1, 2016
0.52 KRW
Jan 1, 2017
0.29 KRW
Jan 1, 2018
0.35 KRW
Jan 1, 2019
0.30 KRW
Jan 1, 2020
0.15 KRW
Jan 1, 2021
0.11 KRW
The HLB BioStep Co Div.-Adj. PEG history
YEARDiv.-Adj. PEGYoY
0.11-24.74%
0.15-49.46%
0.30-15.28%
0.35+21.38%
0.29-43.56%
0.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HLB BioStep Co Stock analysis

What does HLB BioStep Co do? HLB bioStep Co., Ltd. generates revenue through three business segments. The Non-clinical Test Consignment Agency Business segment provides testing for new drugs and evaluates efficacy, pharmacodynamics, and safety of substances. The Bioinfra Business segment designs, constructs, and maintains animal laboratories while delivering equipment. The Pet Medical Business segment develops veterinary medicine and sells companion animal products. Clients include pharmaceutical companies requiring non-clinical testing, research institutions needing laboratory infrastructure, and pet care providers purchasing animal health products. The company's Non-clinical Test Consignment Agency Business serves pharmaceutical firms seeking pre-market substance evaluation. Bioinfra Business targets institutions requiring specialized animal lab facilities and equipment. Pet Medical Business supplies veterinary medicine to pet health markets. Revenue streams are derived from testing fees, laboratory services, equipment sales, and product distribution. HLB bioStep's segments align with pharmaceutical development cycles, animal research infrastructure needs, and companion animal healthcare demands. Testing services are contracted by drug developers, lab construction by research organizations, and veterinary products sold to pet care retailers. The company monetizes expertise in non-clinical testing, lab management, and veterinary product distribution without direct consumer sales. HLB BioStep Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HLB BioStep Co stock

Dividend-Adjusted PEG Ratio of HLB BioStep Co is 0.11 in 2021.

Dividend-Adjusted PEG Ratio of HLB BioStep Co changed from 0.15 to 0.11, representing a -24.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Dividend-Adjusted PEG Ratio HLB BioStep Co since 2006 – with annual values, charts, and detailed analysis.

The dividend-adjusted PEG ratio factors in dividend yield alongside earnings growth, providing a more complete valuation for income-paying stocks.

To evaluate Dividend-Adjusted PEG Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Dividend-Adjusted PEG Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Dividend-Adjusted PEG Ratio's HLB BioStep Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — HLB BioStep Co

All Key Metrics — HLB BioStep Co